Boston, Massachusetts 02115


Obstructive Sleep Apnea (OSA) is characterized by collapse of one or more pharyngeal structures during sleep (velum, tongue base, lateral walls, epiglottis). Structure-specific therapies for OSA have emerged as alternatives to positive airway pressure (PAP). Oral appliance (OA) therapy is increasingly being indicated for OSA treatment, although a complete response occurs in approximately 50% of patients. In general, OA devices are designed to maintain the mandible and/or tongue in a protruded posture during sleep, preventing upper airway obstruction. Limited studies in awake or sedated patients have demonstrated the effects of mandibular advancement on aspects of pharyngeal structure and function. The objective of the proposed research is to fully characterize upper airway collapse in OSA patients during natural sleep and use this information to understand why some patients appear to exhibit a large improvement in pharyngeal collapsibility whereas others do not.

Study summary:

OSA patients will undergo a baseline sleep endoscopy study to identify the site of pharyngeal collapse. Subsequently, they will undergo two clinical polysomnographies (PSGs) to measure the effect of an oral appliance (a site specific therapy) on upper airway collapsibility and sleep apnea severity. During the first hour of each clinical PSG, the passive pharyngeal collapsibility will be determined using the standard 5-breath continuous positive airway pressure (CPAP) drop method. During the remainder of the night, patients will be monitored to determine sleep apnea severity (apnea-hypopnea index). These measurements will allow the investigators to determine which pharyngeal collapsing site responds best (both in terms of collapsibility and AHI) to mandibular advancement with an oral appliance. Patients who have their own oral appliance will be recruited. In addition, patients without an oral appliance will be provided with a temporary oral appliance for the study.


Inclusion Criteria: - Patients with Obstructive Sleep Apnea Exclusion Criteria: - Any unstable cardiac condition (other than well controlled hypertension) or pulmonary problems. - Any medication known to influence breathing, sleep/arousal or muscle physiology - Concurrent sleep disorders (insomnia, narcolepsy, central sleep apnea or parasomnia) - Claustrophobia - Inability to sleep supine - Periodontal disease and/or insufficient number of teeth - Allergy to lidocaine or oxymetazoline hydrochloride - For women: Pregnancy



Primary Contact:

Principal Investigator
David A Wellman, PhD
Brigham and Women's Hospital

Lauren B Hess, BS
Phone: (617) 732-8976

Backup Contact:


Location Contact:

Boston, Massachusetts 02115
United States

Lauren B Hess, BS
Phone: 617-732-8976

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.